Role of drug metabolism in drug discovery and development

Medicinal Research Reviews

Volumn 21, Issue 5, 2001, Pages 397-411

  Kumar, Gondi N ^a   Surapaneni, Sekhar ^a  

^a AMGEN INC   (United States)

Author keywords

Cytochrome P450; Drug discovery; Drug metabolism; Drug drug interactions

Indexed keywords

AMFEBUTAMONE; BUFURALOL; CAFFEINE; CHLORZOXAZONE; COUMARIN; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HEME; MEPHENYTOIN; MIDAZOLAM; PACLITAXEL; TOLBUTAMIDE;

CONFERENCE PAPER; COVALENT BOND; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG INTERACTION; DRUG METABOLISM; DRUG RESEARCH; ENZYME INACTIVATION; ENZYME INDUCTION; METABOLIC ACTIVATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG INTERACTIONS; ENZYME INDUCTION; HEME; HUMANS; IRON; PHARMACEUTICAL PREPARATIONS;

EID: 0034885012     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.1016     Document Type: Conference Paper

References (39)

1. Biotransformation of xenobiotics
2. Role of pharmacokinetics and metabolism in drug discovery and development
3. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics
4. The P450 superfamily: Update on new sequences, gene mapping, accession number, early trivial names of enzyme, and nomenclature
5. Human Cytochrome P450 enzymes: A status report summarizing their reactions. Substrates, inducers and inhibitors
6. The human hepatic cytochrome P450 involved in drug metabolism
7. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogen, and toxic chemicals. Studies with liver microsomes of 30 Japanese and 30 Caucasians
8. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
9. Metabolic activation of carcinogens
10. Role of cytochrome P450 1A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity
11. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: Role of cytochrome P4502C and 3A subfamily members
12. Properties of cytochrome P450 isoenzymes and their substrates part 1: Active site characteristics
13. The human CYP3A subfamily practical considerations
14. Characterization of inter- and intra-intestinal differences in human CYP3A-dependent metabolism
15. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes
16. Rifampin drastically reduces plasma concentrations and effect of oral midazolam
17. Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site
18. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6
19. Quantitative relationships between structure and microsomal oxidation rate of 1,4-dihydropyridines
20. Sulfation of minoxidil by liver sulfotranferase
21. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes
22. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase
23. Substrate interactions with Cytochrome P450
24. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
25. P450 interaction with HIV protease inhibitors: Relationship between metabolic stability, inhibitory potency and P450 binding spectra
26. Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolides antibiotics; a new class of agens
27. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
28. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculoviris-expressed and purified human cytochromes P450 2E1 and 2A6
29. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal Cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A
30. Identification of tamoxifen-DNA adducts formed by 4-hydroxyltamoxifen quninone methide
31. Bioactivation and irreversible binding of the cognition activator tachrine using human and rat liver microsomal preparations: Species difference
32. Inhibition and induction of cytochrome P450 and the clinical implications
33. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
34. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
35. FDA evaluation using in vitro metabolism to predict and iterpret in vivo metabolic drug-drug interactions: Impact on labeling
36. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents
37. Relevance of induction of human drug-metabolizaing enzymes: Pharmacological, and toxicological implications
38. Molecular mechanisms of Cytochrome P-450 induction by xenobiotics: An expanded role for nuclear hormone receptors
39. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR